Drug Type Small molecule drug |
Synonyms Orteronel (JAN/USAN), TAK-700 |
Target |
Action inhibitors |
Mechanism CYP17A1 inhibitors(Steroid 17-alpha-hydroxylase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
License Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC18H17N3O2 |
InChIKeyOZPFIJIOIVJZMN-SFHVURJKSA-N |
CAS Registry566939-85-3 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hormone-dependent prostate cancer | Phase 3 | United States | 08 Mar 2013 | |
Metastatic Prostate Carcinoma | Phase 3 | United States | 08 Mar 2013 | |
Metastatic castration-resistant prostate cancer | Phase 3 | United States | 01 Oct 2010 | |
Metastatic castration-resistant prostate cancer | Phase 3 | Japan | 01 Oct 2010 | |
Metastatic castration-resistant prostate cancer | Phase 3 | Australia | 01 Oct 2010 | |
Metastatic castration-resistant prostate cancer | Phase 3 | Austria | 01 Oct 2010 | |
Metastatic castration-resistant prostate cancer | Phase 3 | Belarus | 01 Oct 2010 | |
Metastatic castration-resistant prostate cancer | Phase 3 | Belgium | 01 Oct 2010 | |
Metastatic castration-resistant prostate cancer | Phase 3 | Brazil | 01 Oct 2010 | |
Metastatic castration-resistant prostate cancer | Phase 3 | Bulgaria | 01 Oct 2010 |
Phase 2 | 10 | wbesozwipa(iuragstmya) = rkptywdqra ltnfopkgqu (xvrbrmqegy, 9.6 - 70.4) | Positive | 30 Dec 2024 | |||
Phase 3 | 1,279 | ADT±orteronel (Black patients) | omtwpjevgu(hmztnfxdgd) = PSA responses (≤ 0.2 ng/mL) at month 7 were similar in both groups. nrqfsnuvzn (kllvjumykh ) View more | Positive | 31 May 2023 | ||
ADT±orteronel (White patients) | |||||||
Phase 3 | 1,313 | Androgen deprivation + Orteronel | xonunadnum(wvgwazfvdc): HR = 1.58 (95% CI, 1.09 - 2.29) View more | - | 31 May 2023 | ||
Androgen deprivation | |||||||
Phase 3 | 1,279 | Orteroneleronel | ealnidiquw(sqnrdyonas) = meeypwjmkx ovzjdybtyk (tbwlakdkwz ) View more | - | 31 May 2023 | ||
Bicalutamidetamide | ealnidiquw(sqnrdyonas) = hulqqctodc ovzjdybtyk (tbwlakdkwz ) View more | ||||||
Phase 3 | 239 | Radiation therapy (ADT + RT) | nsomphcmqi = ebpidcekqi urjwvuhref (reuxeoaqyp, gtsvbgagnu - qwrtrycrkl) View more | - | 18 Apr 2023 | ||
Radiation therapy+TAK-700 (TAK-700 + ADT + RT) | nsomphcmqi = slzatepjgh urjwvuhref (reuxeoaqyp, ddqnvtjodr - paikaobfqf) View more | ||||||
Phase 3 | - | Orteronel + ADT | fhehkjlpdo(unzqxjpyif) = ejoagcbfex hysjvcvyyr (ymaxeieepn ) View more | Negative | 01 Oct 2022 | ||
Bicalutamide + ADT | fhehkjlpdo(unzqxjpyif) = zvxnrgziqd hysjvcvyyr (ymaxeieepn ) View more | ||||||
Phase 3 | 1,313 | (LHRHa + TAK-700) | gwiattwuhz(xtuhtffbmu) = mcogkbbduy btiugjerko (mewrrsubtt, ihqpaygehv - oimksozvtt) View more | - | 08 Sep 2022 | ||
(LHRHa + Bicalutamide) | gwiattwuhz(xtuhtffbmu) = rrbgfvukmy btiugjerko (mewrrsubtt, tqhmxkfmlz - sllztcuoni) View more | ||||||
Phase 2 | Metastatic Triple-Negative Breast Carcinoma androgen receptor (AR) | 26 | Orteronel 300 mg PO BID | ghnxodmyae(qafydtwokn) = 4 patients reporting SAEs (G2 pneumonitis, G2 chest pain and G2 peripheral edema, G4 prolonged QT and G4 hypokalemia) lgsktqdjgs (haxxnlewod ) View more | Negative | 15 Feb 2021 | |
Phase 1/2 | 38 | (Phase 1: Orteronel 200 mg BID + Docetaxel + Prednisone) | grbdvzmmfr = kuakxtwjgh zqcvmtdbcc (qpeisynxar, oirdqnhalg - whlvlvizbu) View more | - | 30 Jul 2019 | ||
(Phase 1: Orteronel 400 mg BID + Docetaxel + Prednisone) | grbdvzmmfr = byldpcjyge zqcvmtdbcc (qpeisynxar, nndcwveoxq - wcwfucjkij) View more | ||||||
Phase 3 | 1,099 | Orteronel Placebo+prednisone (Placebo + Prednisone) | mvbniomlkk(dfpkwotpyi) = pcourhpiig lqqpesxvgg (jhtwiuvsni, mrxectlcfg - rmjxxalztk) View more | - | 19 Dec 2018 | ||
(Orteronel + Prednisone) | mvbniomlkk(dfpkwotpyi) = eklpudkwuo lqqpesxvgg (jhtwiuvsni, owelqvthut - rsndqfcrqf) View more |